دورية أكاديمية
First-year cumulative myeloperoxidase-ANCA titres are associated with all-cause mortality in patients with microscopic polyangiitis.
| العنوان: | First-year cumulative myeloperoxidase-ANCA titres are associated with all-cause mortality in patients with microscopic polyangiitis. |
|---|---|
| المؤلفون: | Rah W; Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea., Song JJ; Division of Rheumatology, Department of Internal Medicine, and Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea., Park YB; Division of Rheumatology, Department of Internal Medicine, and Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee SW; Division of Rheumatology, Department of Internal Medicine, and Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea. sangwonlee@yuhs.ac. |
| المصدر: | Clinical and experimental rheumatology [Clin Exp Rheumatol] 2024 Apr; Vol. 42 (4), pp. 887-894. Date of Electronic Publication: 2024 Mar 22. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Clinical And Experimental Rheumatology S.A.S Country of Publication: Italy NLM ID: 8308521 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0392-856X (Print) Linking ISSN: 0392856X NLM ISO Abbreviation: Clin Exp Rheumatol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Pisa : Clinical And Experimental Rheumatology S.A.S Original Publication: Pisa, Italy : Pacini editore, [1983- |
| مواضيع طبية MeSH: | Microscopic Polyangiitis*/mortality , Microscopic Polyangiitis*/immunology , Microscopic Polyangiitis*/blood , Microscopic Polyangiitis*/diagnosis , Peroxidase*/immunology , Peroxidase*/blood , Antibodies, Antineutrophil Cytoplasmic*/blood , Antibodies, Antineutrophil Cytoplasmic*/immunology , Biomarkers*/blood, Humans ; Female ; Male ; Middle Aged ; Aged ; Cause of Death ; Recurrence ; Time Factors ; Myeloblastin/immunology ; Risk Factors ; Prognosis ; Predictive Value of Tests ; Retrospective Studies |
| مستخلص: | Objectives: We investigated whether first-year cumulative myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA) and proteinase 3 (PR3)-ANCA titres were associated with all-cause mortality and relapse during follow-up in patients with microscopic polyangiitis (MPA) and granMETHODS: Altogether, 74 patients with MPA and 40 with GPA were included in this study. Their clinical data at diagnosis were collected. First-year cumulative ANCA titres were defined as the area under the curve (AUC) of ANCA titres during the first year after MPA or GPA diagnosis, which was obtained using the trapezoidal rule. All-cause mortality and relapse were considered poor outcomes of MPA and GPA. Results: The median ages of patients with MPA and GPA were 65.5 and 60.5 years, respectively. No significant correlation was observed between ANCA titres at diagnosis and concurrent MPA and GPA activity or the inflammatory burden. First-year cumulative MPO-ANCA titres exhibited a significant AUC for all-cause mortality during follow-up in patients with MPA. The optimal cut-off of first-year cumulative MPO-ANCA titres for all-cause mortality was determined as 720.8 IU/mL using receiver operating characteristic curve analysis. MPA patients with first-year cumulative MPO-ANCA titres ≥720.8 IU/mL exhibited a significantly higher risk for all-cause mortality than those without (relative risk 13.250). Additionally, MPA patients with first-year cumulative MPO-ANCA titres ≥720.8 IU/mL exhibited a significantly lower cumulative patients' survival rate than those without. Conclusions: This is the first study to demonstrate the association between first-year cumulative MPO-ANCA titres and all-cause mortality during follow-up in patients with MPA. |
| المشرفين على المادة: | EC 1.11.1.7 (Peroxidase) 0 (Antibodies, Antineutrophil Cytoplasmic) EC 1.11.1.7 (MPO protein, human) 0 (Biomarkers) EC 3.4.21.76 (Myeloblastin) |
| تواريخ الأحداث: | Date Created: 20240325 Date Completed: 20240429 Latest Revision: 20240524 |
| رمز التحديث: | 20240524 |
| DOI: | 10.55563/clinexprheumatol/jui6xj |
| PMID: | 38526013 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0392-856X |
|---|---|
| DOI: | 10.55563/clinexprheumatol/jui6xj |